Dipartimento di Farmacia e Biotecnologie FaBiT, Università di Bologna, Via Belmeloro 6, 40126 Bologna, Italy.
Eur J Med Chem. 2013 Oct;68:412-21. doi: 10.1016/j.ejmech.2013.07.052. Epub 2013 Aug 13.
The synthesis of new imidazo[2,1-b]thiazoles bearing phenolic groups is reported. These compounds and some previously described analogs were evaluated as antioxidant agents with three chemical model systems, and cancer chemopreventive potential was examined by inhibition of NO production, TNF-α activated NFκB activity, and aromatase activity, as well as induction of QR1 and RXRE binding. Two of the test compounds, 9 and 12, displayed promising activity by inhibiting iNOS, NFκB and aromatase in dose-dependent manner, with IC50 values in low micromolar range. The same compounds activated QR1 in a bifunctional manner. When incubated with human liver microsomes, the active compounds were further hydroxylated on the parent ring system, suggesting the next logical step in the development of these promising leads will entail synthetic production of metabolites followed by additional assessment of biological activity.
报道了新型含酚基的咪唑并[2,1-b]噻唑的合成。这些化合物和一些以前描述的类似物被用作三种化学模型系统的抗氧化剂进行评估,并通过抑制 NO 产生、TNF-α 激活的 NFκB 活性和芳香酶活性以及诱导 QR1 和 RXRE 结合来检测其癌症化学预防潜力。两种测试化合物 9 和 12 通过剂量依赖性方式抑制 iNOS、NFκB 和芳香酶,显示出有希望的活性,IC50 值在低微摩尔范围内。相同的化合物以双功能方式激活 QR1。当与人肝微粒体一起孵育时,活性化合物在母体环系统上进一步羟基化,这表明这些有前途的先导化合物的下一步合理发展将需要合成代谢物的生产,然后再进一步评估生物活性。